Skip to main content

Table 3 Patients’ statistics (with survival comparison), each patient as single individual

From: Clinical versus histological grading in the assessment of cutaneous graft versus host disease

Patient statistics (with survival comparison)
Feature Grouping/specifics Frequency % p value
Number of patients N 110 100.0%  
Survival patients overall (years) Mean 2.96 (SD 2.47)   
Gender Male 72 65.5% 0.526
Female 38 34.5%  
Age Mean 45.9 (SD 17.5)   
0–10 8 7.3% 0.328
10–20 4 3.6%  
20–30 8 7.3%  
30–40 11 10.0%  
40–50 19 17.3%  
50–60 36 32.7%  
60–70 24 21.8%  
Disease Lymphoma 18 16.4% 0.3137
Plasma cell disorders 23 20.9%  
MDS/MPN 12 10.9%  
Bone marrow failure 3 2.7%  
Inherited disorders 6 5.5%  
Metabolic disorders 1 0.9%  
AML 25 22.7%  
CML 3 2.7%  
ALL 11 10.0%  
CLL 8 7.3%  
Donor type Sibling (SIB) 34 30.9% 0.1867
Cord blood (CB) 11 10.0%  
Matched unrelated donor (MUD) 63 57.3%  
Other 2 1.8%  
Conditioning type Myeloablative 17 15.5% 0.2449
Non-myeloablative 72 65.5%  
Reduced intensity 21 19.1%  
Infection after treatment Overall 95 86.4% 0.1582
  CMV 32 29.1% 0.9485
  HHV6 10 9.1% 0.2073
  EBV 7 6.4% 0.6031
  Aspergillus 11 10.0% 0.2082
  Candida 31 28.2% 0.2318
Clinical GvHD Overall (fully documented) including acute GvHD only (a), both acute and chronic GvHD (b) and chronic GvHD (c) 108 98.2% 0.0037
Acute GvHD only (a) 18 16.4%  
Both acute and chronic GvHD (b) 77 70.0%  
Chronic GvHD only (c) 13 11.8%  
 Clinical acute GvHD (a+b) Mean survival (years) 3.0 (SD 2.6)   
Overall no. of patients with documented acute GvHD (a+b) 95 86.4%  
aGvHD presentation at date skin biopsy (with no. of biopsies) 67 (68) 60.9% 0.0036
  Max. clinical documented aGvHD skin grade reached 66   < 0.0001
 Clinical chronic GvHD (b+c) Mean survival (years) 3.3 (SD 2.5)   
Overall no. of patients with documented chronic GvHD (b+c) 90 81.8%  
cGvHD presentation at date biopsy (with no. of biopsies) 48 (52) 43.6% 0.44
  Progressive 13 (15)   
  Quiescent 6 (7)   
  Late onset aGvHD 19 (20)   
  De Novo 4 (4)   
  Late onset aGvHD after DLI 6 (6)   
Max. clinical documented cGvHD grade reached (including all tracts) 48 43.6% 0.8844
  Max. clinical documented % skin involvement 46 41.8% 0.7622
   0% 6   
   0–25% 15   
   25–50% 25   
   > 50% 0